LEXINGTON, Mass.,
June 21, 2017
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an
immuno-oncology company with a pipeline of immune checkpoint
antibodies and cancer vaccines, announced that GlaxoSmithKline's
shingles vaccine candidate, Shingrix, containing Agenus'
proprietary immune adjuvant, QS-21 Stimulon®, triggered a strong
immune response in elderly patients previously treated with the
current vaccine, Zostavax®, for the prevention of
shingles.
GSK will today present the results from the Phase 3
(Zoster-048) study at the meeting of US Centers for
Disease Control and Prevention's Advisory Committee on Immunization
Practices (ACIP).
"This is an important clinical achievement as it broadens
the target population that can potentially benefit from this highly
efficacious vaccine candidate, which includes our adjuvant, QS-21
Stimulon. QS-21 Stimulon has helped bolster immunogenicity of a
number of development stage vaccines in ways that enable activity,"
said Garo Armen, Ph.D., Agenus CEO
and Chairman of the Board. "Clearly this is a further validation of
our QS-21 Stimulon, which is moving forward in a number of internal
and external vaccine formulations with the potential to offer
benefit for patients."
QS-21 Stimulon is being evaluated in conjunction with
Agenus' neoantigen vaccine, AutoSynVax™, in a Phase 1 clinical
trial, with immunological readouts expected by the end of this
year.
About Agenus
Agenus is
a clinical-stage immuno-oncology company focused on the discovery
and development of therapies that engage the body's immune system
to fight cancer. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing a
number of combination approaches that leverage a broad repertoire
of antibody therapeutics and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support early phase clinical programs. Agenus is
headquartered in Lexington, MA. For more information,
please visit www.agenusbio.com;
information that may be important to investors will be routinely
posted on our website.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company's
product candidates, clinical trial plans and activities and
expected timing for trial results, as well as the expected benefits
of GSK's Shingrix. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Michelle Linn,
781-674-4541
michelle.linn@agenusbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/positive-phase-3-for-gsks-shingles-vaccine-shingrix-with-agenus-qs-21-stimulon-immune-adjuvant-300477507.html
SOURCE Agenus Inc.